Search clinical trials for: ROS1 protein, human

Total 23881 results

USDA Grand Forks Human Nutrition Research Center

Completed

Carotenoid Response to the Intake of Vegetables and Fruits

Resonance Raman Spectroscopy for Dietary Carotenoid Intake

United States
Maastricht University

Completed

Safety Study of Vitamin K2 During Anticoagulation in Human Volunteers

Healthy

Netherlands
Puerta de Hierro University Hospital

Completed

B-cryptoxanthin and Phytosterols on Bone Remodeling and Cardiovascular Risk Factors

Postmenopausal Disorder

Spain
University College, London

Completed

Biliary Stenting With or Without Photodynamic Therapy in Treating Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors That Cannot Be Removed by Surgery (Photostent-02)

Gallbladder Cancer | Extrahepatic Bile Duct Cancer

United Kingdom
AdventHealth Translational Research Institute

Completed

Effects of Glucagon Administration on Energy Expenditure (GLEE)

Obesity | Hyperglucagonemia

United States
University of Utah
Abbott

Completed

Skin and Serum Carotenoids in Preterm Infants Fed on a Formula Supplemented With Carotenoids

Retinopathy of Prematurity

United States
Queen Elizabeth II Health Sciences Centre
Nova Scotia Health Research Foundation

Completed

Prevention of Instent Renarrowing With Aggressive Glucose Lowering With Pioglitazone in Diabetic Patients (PPAR-G)

Coronary Artery Disease | Type 2 Diabetes Mellitus | Angina Pectoris | Percutaneous Coronary Intervention

Canada
Addario Lung Cancer Medical Institute

Completed

ALCMI-006: A Prospective Biospecimen Collection Study From Patients With ROS1-Fusion Positive Tumors

ROS1-fusion Positive Tumor

United States
Takeda

Completed

A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors

Carcinoma, Advanced ALK+ or ROS1+Non-Small-Cell Lung, Neoplasm, Advanced ALK+ or ROS1+Solid Tumors

Spain, Italy, Netherlands, France
Hoffmann-La Roche

No longer available

Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions

Cancers With NTRK, ROS1, or ALK Gene Fusions

United States
Shanghai Fosun Pharmaceutical Industrial Development...

Recruiting

A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients

Advanced Solid Tumor | Advanced Cancer | Lung Cancer, Nonsmall Cell

China
Pfizer

Recruiting

Crizotinib Continuation Clinical Study

NSCLC | IMT | ALCL

China, Taiwan, Japan, Russian Federation, Italy
National Cancer Institute (NCI)

Active, not recruiting

Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
Hoffmann-La Roche

Active, not recruiting

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)

Melanoma | Renal Cell Carcinoma | Adult Solid Tumor | Breast Cancer | Head and Neck Neoplasms | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Neuroendocrine Tumors | Lymphoma, Large-Cell, Anaplastic | Cholangiocarcinoma | Papillary Thyroid Cancer | Sarcomas | Salivary Gland Cancers and other conditions

United States, China, Korea, Republic of, Australia, Taiwan, France, Spain, United Kingdom, Hong Kong, Belgium, Italy, Germany, Japan, Singapore, Netherlands, Poland
Pfizer

No longer available

Crizotinib Expanded Access Protocol For ROS1 Positive NSCLC

Neoplasms | Carcinoma, Non-Small-Cell Lung

Japan
GlaxoSmithKline

Withdrawn

A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer

Cancer
Guangzhou JOYO Pharma Co., Ltd

Recruiting

Study of Oral JYP0322 in Patients With Locally Advanced or Metastatic Cancer Targeting ROS1 Molecular Fusion.

Lung Neoplasms | Brain Neoplasms | Protein Kinase Inhibitors | Other Protocol Specified Criteria

China
Pfizer

Completed

Study to IDEntify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS)

Non-Small Cell Lung Cancer

Spain
Jiangsu Simcere Pharmaceutical Co., Ltd.

Recruiting

An Open Label, Multi-center, Phase I Clinical Study to Evaluate the Safety, Effectiveness and Pharmacokinetic Characteristics of SIM1803-1A in Patients With Locally Advanced/Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion Mutations.

Advanced or Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion

China
MedSIR
Medical University of Vienna

Not yet recruiting

REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis (REPOSE)

NSCLC | Brain Metastases | ROS1 Gene Rearrangement
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator...

Not yet recruiting

Pharmacogenomics IND EXEMPT SNP Clinical Study - Crizotinib and Single Nucleotide Polymorphisms (Drugs-SNPs)

Non-Small Cell Lung Cancer

United States
Turning Point Therapeutics, Inc.

Recruiting

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Lymphoma | Locally Advanced Solid Tumors | Metastatic Solid Tumors | Primary CNS Tumors

United States, Korea, Republic of, Spain, Singapore, Taiwan, Australia, Italy, Canada, France, Denmark, United Kingdom
Turning Point Therapeutics, Inc.
Zai Lab (Shanghai) Co., Ltd.

Recruiting

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)

Locally Advanced Solid Tumors | Metastatic Solid Tumors

United States, China, Japan, Australia, Belgium, Canada, Denmark, France, Germany, Hong Kong, Hungary, Italy, Korea, Democratic People's Republic of, Korea, Republic of, Netherlands, Poland, Singapore, Spain, Taiwan, United Kingdom
Massachusetts General Hospital
National Cancer Institute (NCI)

Completed

A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC

Non-small Cell Lung Cancer Metastatic | Targetable Oncogenes (EGFR, ALK, ROS1)

United States
Hoffmann-La Roche

Active, not recruiting

Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options (STARTRK-NG)

Solid Tumors | CNS Tumors

United States, Spain, Korea, Republic of, Canada, Germany, United Kingdom, China, Italy, Hong Kong, France, Taiwan
Centre Leon Berard
Hoffmann-La Roche

Active, not recruiting

RNASARC - Molecular Screening Program of Soft Tissue Sarcomas With Complex Genomic Profile to Detect NTRK1/2/3, ROS1 or ALK Gene Fusions. (RNASARC)

Soft Tissue Sarcoma | Metastatic Cancer | Advanced Cancer

France
Daiichi Sankyo Co., Ltd.

Completed

Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant Tumors

Advanced Solid Malignant Tumors

Japan
Novartis Pharmaceuticals

Terminated

Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE) (SIGNATURE)

Tumors With Aberrations in ALK or ROS1

United States
Betta Pharmaceuticals Co., Ltd.

Unknown

X-396 Capsule in Advanced NSCLC Patients With ROS1 Gene Rearrangement

Lung Cancer | ROS1 Gene Rearrangement

China
Sameek Roychowdhury
National Cancer Institute (NCI)

Withdrawn

Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers

Locally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | ALK Gene Mutation | Metastatic Malignant Neoplasm in the Brain | Advanced Malignant Neoplasm | ALK Fusion Protein Expression | Metastatic Malignant Neoplasm in the Central Nervous System | ROS1 Gene Mutation | ALK Gene... and other conditions

United States
Bristol-Myers Squibb
Zai Lab (Shanghai) Co., Ltd.

Recruiting

A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

Carcinoma, Non-Small-Cell Lung

Japan, China, Canada, Spain, Germany, Korea, Republic of, Austria, Brazil, Greece, France, United States, Italy, Argentina, Chile, Hungary, India, Turkey, Romania, Switzerland, Netherlands, Poland
University of Colorado, Denver
Janssen Research & Development, LLC

Recruiting

Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations

Lung Cancer | Non Small Cell Lung Cancer

United States
Pfizer

Active, not recruiting

PF-07284892 in Participants With Advanced Solid Tumors

Solid Tumor

United States
Pfizer

No longer available

Crizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients

Neoplasm

United States
University of Cologne
Pfizer; Spanish Lung Cancer Group

Completed

EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung Cancer (EUCROSS)

Adenocarcinoma | NSCLC | Lung Cancer

Germany, Spain, Switzerland
Pfizer
OxOnc Development LP

Completed

Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC

Non Small Cell Lung Cancer | Crizotinib | ROS1 Proto Oncogene

Korea, Republic of, China, Taiwan, Japan
Hoffmann-La Roche

Recruiting

A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases

Carcinoma, Non-Small-Cell Lung

Brazil, China, France, Croatia, Greece, Italy, Mexico, Spain, India, Netherlands, Romania, Sweden, Thailand, Lebanon, Turkey, Slovakia, Jordan, Russian Federation, Germany
Centre Hospitalier Intercommunal Creteil

Completed

Retrospective, Observational, Multi-center Study Evaluating the Efficacy and Tolerance of Brigatinib in the Management of Rearranged CBNPC ROS1 (BRIGAROS)

Lung Cancer ROS Translocated

France
Fondazione Ricerca Traslazionale
Clinical research technology Srl

Active, not recruiting

PF-06463922 for Crizotinib Pretreated ROS1 Positive Non-small-cell Lung Cancer (PFROST)

Carcinoma, Non-Small-Cell Lung

Italy
Yonsei University

Unknown

A Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement

Non-small Cell Lung Cancer Harboring ROS1 Rearrangement

Korea, Republic of
Fondazione Ricerca Traslazionale

Unknown

Crizotinib in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or ROS1 Translocation (METROS) (METROS)

Carcinoma, Non-Small-Cell Lung

Italy
Pfizer
French College of General Hospital Pneumologists (CPHG)

Completed

Descriptive Observational Study ALK-2016-CPHG (ALK2016CPHG)

NSCLC | Crizotinib | ALK Gene Rearrangement or ROS1 Gene Rearrangement

France
Intergroupe Francophone de Cancerologie Thoracique

Recruiting

Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)

Non Small Cell Lung Cancer Metastatic

France
Hunan Province Tumor Hospital

Recruiting

Real World Study on First Line Crizotinib in ROS1 Rearranged Advanced Non-squamous Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Unilever R&D
St. John's Research Institute

Completed

Effect of Bacopa Monniera Extract on Cognition and Anxiety and Exploration of PK Properties (Yaaddasht)

Anxiety | Pharmacokinetics | Cognition

India
Pfizer

Recruiting

Safety and Efficacy of Xalkori ROS1

Non-small Cell Lung Cancer

Japan
Hoffmann-La Roche

Completed

Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations. (STARTRK-1)

Locally Advanced Solid Tumors | Metastatic Solid Tumors

United States, Korea, Republic of
National Cancer Center, Korea

Recruiting

Study of Lorlatinib in ROS1 Rearranged NSCLC

Nonsmall Cell Lung Cancer

Korea, Republic of
Shanghai Chest Hospital

Recruiting

Neoadjuvant Therapy in Resectable Non-Small Cell Lung Cancer Stages IIB-IIIB

Non Small Cell Lung Cancer

China
AnHeart Therapeutics Inc.

Recruiting

Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC (TRUST-II)

Non Small Cell Lung Cancer

United States, Spain, France, Italy, Japan, Korea, Republic of, Canada, China, Poland

Search clinical trials for: ROS1 protein, human

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Paraguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations